SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials
Patient-reported outcomes (PROs) are used in clinical trials to provide valuable evidence on
the impact of disease and treatment on patients' symptoms, function and quality of life. High …
the impact of disease and treatment on patients' symptoms, function and quality of life. High …
Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series
J McDonald, J Sayers, SD Anker… - Journal of cachexia …, 2023 - Wiley Online Library
In cancer cachexia trials, measures of physical function are commonly used as endpoints.
For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be …
For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be …
Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of …
E Fokas, A Schlenska-Lange, B Polat, G Klautke… - JAMA …, 2022 - jamanetwork.com
Importance Total neoadjuvant therapy has been increasingly adopted for multimodal rectal
cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy …
cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy …
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label …
PR Galle, RS Finn, S Qin, M Ikeda, AX Zhu… - The Lancet …, 2021 - thelancet.com
Background Understanding patients' experience of cancer treatment is important. We aimed
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …
to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus …
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200) …
E Pujade-Lauraine, K Fujiwara, JA Ledermann… - The Lancet …, 2021 - thelancet.com
Background Most patients with ovarian cancer will relapse after receiving frontline platinum-
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
based chemotherapy and eventually develop platinum-resistant or platinum-refractory …
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a …
J Huang, J Xu, Y Chen, W Zhuang, Y Zhang… - The Lancet …, 2020 - thelancet.com
Background Patients with advanced or metastatic oesophageal squamous cell carcinoma
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
have poor prognosis and few treatment options after first-line therapy. We aimed to assess …
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised …
YP Chen, X Liu, Q Zhou, KY Yang, F Jin, XD Zhu, M Shi… - The Lancet, 2021 - thelancet.com
Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
[HTML][HTML] Integrated Geriatric Assessment and Treatment Effectiveness (INTEGERATE) in older people with cancer starting systemic anticancer treatment in Australia: a …
Background The effectiveness of comprehensive geriatric assessment (CGA) in improving
health outcomes in cancer settings is unclear. We evaluated whether CGA can improve …
health outcomes in cancer settings is unclear. We evaluated whether CGA can improve …
Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal …
Importance Concurrent chemoradiotherapy has been the standard treatment for stage II
nasopharyngeal carcinoma (NPC) based on data using 2-dimensional conventional …
nasopharyngeal carcinoma (NPC) based on data using 2-dimensional conventional …
[HTML][HTML] General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European …
Abstract Objective The European Organisation for Research and Treatment of Cancer
(EORTC) QLQ-C30 health-related quality of life questionnaire is one of the most widely used …
(EORTC) QLQ-C30 health-related quality of life questionnaire is one of the most widely used …